SCHEMBL13102440

SCHEMBL13102440

Cc1cccc2c(=O)n(NC(=O)Cc3ccc(F)cc3)c(C(F)(F)F)nc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.43
LMNA P02545 4/20 0.43
HTT P42858 2/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
CTNNB1 P35222 1/20 0.42
TCF7L2 Q9NQB0 1/20 0.42
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
USP2 O75604 2/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TNKS O95271 1/20 0.38
TNKS2 Q9H2K2 1/20 0.38
PARP2 Q9UGN5 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13102269 0.93 ALDH1A1 (0.43) ALDH1A1LMNAHTTKMT2AMEN1
SCHEMBL13101717 0.92 ALDH1A1 (0.49) ALDH1A1LMNAHTTKMT2AMEN1
SCHEMBL13101689 0.91 ALDH1A1 (0.42) ALDH1A1LMNAHTTKMT2AMEN1
SCHEMBL13101711 0.89 ALDH1A1 (0.43) ALDH1A1LMNAHTTKMT2AMEN1
SCHEMBL13102006 0.88 CTNNB1 (0.44) ALDH1A1LMNAHTTKMT2AMEN1
SCHEMBL13101686 0.88 ALDH1A1 (0.43) ALDH1A1LMNAHTTKMT2AMEN1
SCHEMBL13101704 0.86 ALDH1A1 (0.42) ALDH1A1LMNAHTTKMT2AMEN1
SCHEMBL3058348 0.85 ALDH1A1 (0.47) ALDH1A1LMNAHTTKMT2AMEN1
SCHEMBL13102291 0.85 ALDH1A1 (0.41) ALDH1A1LMNAHTTKMT2AMEN1
SCHEMBL13102107 0.84 ALDH1A1 (0.48) ALDH1A1LMNAHTTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329713-B2 Fused ring heterocycles as potassium channel modulators ICAGEN INC. (US) 2012-12-11 US disclosed
US-20100273784-A1 FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273784-A1 FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS KCNK17, KCNJ2, KCNJ1 ALDH1A1 2354/4885LMNA 1121/4885HTT 329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.